Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00461058 · ClinicalTrials.gov registry record · Phase 2

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.

A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 2
Development phase
14
Enrollment target
20
Study locations

NCT00461058: Completed Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Hoffmann-La Roche.

NCT00461058 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Hoffmann-La Roche. The registered enrollment target is 14 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00461058, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 2
Development phase
14 participants
Enrollment target
20
Study locations

Study Summary

This 2 arm study will compare the safety, tolerability and efficacy of aleglitazar and Actos in patients with type 2 diabetes and symptomatic NYHA class II heart failure. Eligible patients will be randomized to receive either aleglitazar, titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily, or Actos, titrated to an individual maximum tolerated dose up to 45mg p.o. daily, in addition to prescribed diabetes therapy where applicable. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Conditions Studied

Diabetes Mellitus, Type 2

Interventions

  • DRUG Actos
  • DRUG aleglitazar

Study Locations (20)

Other

  • - Ashkelon
  • - Haifa
  • - Kfar Saba
  • - Culiacán
  • - Guadalajara
  • - Metepec
  • - Mexico City
  • - Mexico City
  • - Monterrey
  • - Pachuca

California

  • - Carmichael
  • - Loma Linda
  • - Long Beach

Oklahoma

  • - Oklahoma City
  • - Tulsa

Arkansas

  • - Jonesboro

Florida

  • - Jacksonville

Louisiana

  • - Slidell

Minnesota

  • - Minneapolis

Ohio

  • - Cleveland

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2007-05
Est. Completion 2007-12
Phase Phase 2
Hoffmann-La Roche

909 total trials

What the finished NCT00461058 record still lists

NCT00461058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Actos is the first listed.

NCT00461058 names 20 study sites across 8 states, led by Other, California, Oklahoma.

Frequently Asked Questions

What is clinical trial NCT00461058 about?

NCT00461058 is a clinical study titled "A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.". This 2 arm study will compare the safety, tolerability and efficacy of aleglitazar and Actos in patients with type 2 diabetes and symptomatic NYHA class II heart failure. Eligible patients will be randomized to receive either aleglitazar, titrated to an individual maximum tolerated dose up to 0.3mg ...

What is the current status of trial NCT00461058?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-05. Estimated completion is 2007-12.

What conditions does trial NCT00461058 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT00461058?

The interventions under investigation include: Actos (DRUG), aleglitazar (DRUG).

Who is sponsoring clinical trial NCT00461058?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00461058 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00461058's enrollment target sits among peer trials

14 339th of 348 higher than 9 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00461058, the US trial registry maintained by the National Library of Medicine. NCT00461058 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.